Linked Life Data

15632466

Source:http://linkedlifedata.com/resource/pubmed/id/15632466

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-1-5
pubmed:abstractText
Minodronic acid hydrate is one of the new-generation bisphosphonates containing nitrogen. The drug has an inhibitory effect on bone resorption by suppressing the osteoclastic function. Minodronic acid hydrate is being developed as a therapeutic drug of osteoporosis. In non-clinical study, the inhibitory effect of minodronic acid hydrate on the decrease in the bone mineral density and on the reduction in the bone intensity in ovariectomized rat osteoporosis models. The results of the clinical studies conducted so far showed that minodronic acid hydrate administered once daily for 36 weeks increases the bone mineral density of lumbar spine (L2-4BMD) significantly compared to the placebo group. It was speculated that minodronic acid hydrate has an increasing effect on the bone mineral density that is at least equivalent to that of alendronate and risedronate. It was also expected that the incidence of digestive diseases with minodronic acid hydrate is lower than that with the existing bisphosphonates. At the moment, the Phase III study is being conducted. We expect that minodronic acid hydrate is used for a number of patients with osteoporosis as a potent and safe domestic bisphosphonate in the near future.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0917-5857
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
9-14
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
[Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
pubmed:affiliation
Clinical Planning III Development Planning, ONO Pharmaceutical Co., Ltd.
pubmed:publicationType
Journal Article, English Abstract, Review